127 related articles for article (PubMed ID: 18769118)
21. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
22. EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells.
Takada H; Imadome KI; Shibayama H; Yoshimori M; Wang L; Saitoh Y; Uota S; Yamaoka S; Koyama T; Shimizu N; Yamamoto K; Fujiwara S; Miura O; Arai A
PLoS One; 2017; 12(3):e0174136. PubMed ID: 28346502
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1.
Yamamoto T; Nakamura Y; Kishimoto K; Takeuchi H; Shirakata M; Mitsuya T; Hirai K
Virus Res; 1999 Dec; 65(1):43-55. PubMed ID: 10564752
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
Asano N; Kato S; Nakamura S
Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
[TBL] [Abstract][Full Text] [Related]
25. Monocytes enhance cell proliferation and LMP1 expression of nasal natural killer/T-cell lymphoma cells by cell contact-dependent interaction through membrane-bound IL-15.
Ishii H; Takahara M; Nagato T; Kis LL; Nagy N; Kishibe K; Harabuchi Y; Klein E
Int J Cancer; 2012 Jan; 130(1):48-58. PubMed ID: 21618217
[TBL] [Abstract][Full Text] [Related]
26. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.
Tempera I; De Leo A; Kossenkov AV; Cesaroni M; Song H; Dawany N; Showe L; Lu F; Wikramasinghe P; Lieberman PM
J Virol; 2016 Jan; 90(1):345-55. PubMed ID: 26468528
[TBL] [Abstract][Full Text] [Related]
27. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line.
Szekely L; Chen F; Teramoto N; Ehlin-Henriksson B; Pokrovskaja K; Szeles A; Manneborg-Sandlund A; Löwbeer M; Lennette ET; Klein G
J Gen Virol; 1998 Jun; 79 ( Pt 6)():1445-52. PubMed ID: 9634087
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Epstein-Barr virus (EBV)-positive NK cells isolated from hydroa vacciniforme-like eruptions.
Demachi A; Nagata H; Morio T; Oyoshi MK; Zhang Y; Tabata N; Kimura N; Shimizu N; Yamamoto K
Microbiol Immunol; 2003; 47(7):543-52. PubMed ID: 12953848
[TBL] [Abstract][Full Text] [Related]
29. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
30. The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.
Gru AA; Haverkos BH; Freud AG; Hastings J; Nowacki NB; Barrionuevo C; Vigil CE; Rochford R; Natkunam Y; Baiocchi RA; Porcu P
Curr Hematol Malig Rep; 2015 Dec; 10(4):456-67. PubMed ID: 26449716
[TBL] [Abstract][Full Text] [Related]
31. EBNA1-targeted inhibitors: Novel approaches for the treatment of Epstein-Barr virus-associated cancers.
Jiang L; Xie C; Lung HL; Lo KW; Law GL; Mak NK; Wong KL
Theranostics; 2018; 8(19):5307-5319. PubMed ID: 30555548
[TBL] [Abstract][Full Text] [Related]
32. EBNA1.
Frappier L
Curr Top Microbiol Immunol; 2015; 391():3-34. PubMed ID: 26428370
[TBL] [Abstract][Full Text] [Related]
33. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.
Yin Q; Flemington EK
Virology; 2006 Mar; 346(2):385-93. PubMed ID: 16343579
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus nuclear antigen 1 (EBNA1) induced cytotoxicity in epithelial cells is associated with EBNA1 degradation and processing.
Jones RJ; Smith LJ; Dawson CW; Haigh T; Blake NW; Young LS
Virology; 2003 Sep; 313(2):663-76. PubMed ID: 12954232
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
36. Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.
Oudejans JJ; Dukers DF; Jiwa NM; van den Brule AJ; Grässer FA; de Bruin PC; Horstman A; Vos W; van Gorp J; Middeldorp JM; Meijer CJ
J Clin Pathol; 1996 Nov; 49(11):897-902. PubMed ID: 8944608
[TBL] [Abstract][Full Text] [Related]
37. Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.
AlQarni S; Al-Sheikh Y; Campbell D; Drotar M; Hannigan A; Boyle S; Herzyk P; Kossenkov A; Armfield K; Jamieson L; Bailo M; Lieberman PM; Tsimbouri P; Wilson JB
Oncogene; 2018 Jul; 37(29):3998-4012. PubMed ID: 29691476
[TBL] [Abstract][Full Text] [Related]
38. EBV-NK cells interactions and lymphoproliferative disorders.
Kanegane H; Yachie A; Miyawaki T; Tosato G
Leuk Lymphoma; 1998 May; 29(5-6):491-8. PubMed ID: 9643562
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas.
Jung CK; Lee KY; Kim Y; Han K; Shim SI; Kim BK; Kang CS
Pathol Int; 2001 May; 51(5):355-63. PubMed ID: 11422793
[TBL] [Abstract][Full Text] [Related]
40. B Cell-Specific Transcription Activator PAX5 Recruits p300 To Support EBNA1-Driven Transcription.
Liu CD; Lee HL; Peng CW
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
